Previous close | 1.0400 |
Open | 1.0200 |
Bid | 1.0000 x 0 |
Ask | 1.0200 x 0 |
Day's range | 0.9900 - 1.0200 |
52-week range | 0.9500 - 5.7000 |
Volume | |
Avg. volume | 1,250,645 |
Market cap | 340.987M |
Beta (5Y monthly) | 3.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Aurora Cannabis (NASDAQ: ACB) hit a long-awaited milestone in its most recent earnings results: adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) profitability. Here's a closer look at how Aurora achieved an adjusted EBITDA profit, and whether that should impact your decision to buy the stock or not. Since it's a non-GAAP (adjusted) number, a company can make adjustments to that number that it otherwise wouldn't be able to make to net income.
The cannabis industry in Canada hasn't been in good shape for some time. Growth is almost nonexistent, profits are elusive, and stock prices of marijuana producers have been nosediving. What's particularly telling are the moves of two of the industry's leaders, Aurora Cannabis (NASDAQ: ACB) and Canopy Growth (NASDAQ: CGC).
One sector that's undoubtedly gone from bubble territory to flat-out deflated is cannabis. Many producers saw valuations skyrocket upon the federal legalization of cannabis in Canada in late 2018. U.S.-based multi-state operators (MSOs) like Curaleaf (OTC: CURLF) have certainly had a rough go over the past two years.